Myovant Sciences Ltd. Common Shares (MYOV) Social Stream

Featured Post From StockTwits About MYOV

$MYOV I know prostate cancer . This drug replaces Lupron. It is oral, safer , and leaves the patients system, freeing them from the side effects of hormonal therapy quicker than the injectables. 250000 men diagnosed with prostate cancer yearly. Maybe 75000 new candidates for treatment with this drug. Some short term Some for life. I don’t know the Gyn market. I like the drug. Don’t understand the stock.